Skip to main content
Premium Trial:

Request an Annual Quote

Lab21 Buys Fungal Molecular Diagnostics Firm Myconostica

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Lab21 today announced it has acquired fungal molecular diagnostic firm Myconostica for an undisclosed amount.

The deal will expand Lab21's portfolio of diagnostics and will provide it with its first nucleic acid-based assays. It also provides Lab21 with manufacturing capabilities to develop and produce a range of new biomarker assays, the Cambridge, UK-based firm said.

Based in Manchester, UK, Myconostica has three CE-marked tests available in Europe, Canada, and South Africa, including tests for extracting fungal DNA from human samples and tests for detecting Aspergillus and Pneumocystis jirovecii.

Lab21 will develop global sales of Myconostica's products and launch the Myconostica fungal testing service from its reference laboratory in Greenville, SC, as well as its lab in Cambridge.

The companies said that the global market for fungal testing is about 10 million patients annually.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.